| Issue |
BIO Web Conf.
Volume 237, 2026
2026 8th International Conference on Biotechnology and Biomedicine (ICBB 2026)
|
|
|---|---|---|
| Article Number | 02025 | |
| Number of page(s) | 10 | |
| Section | Pharmacology, Natural Products and Drug Delivery | |
| DOI | https://doi.org/10.1051/bioconf/202623702025 | |
| Published online | 10 June 2026 | |
Bioinformatics Design of a DBV-Specific Multi-Epitope Vaccine
1 School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China
2 Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
a This email address is being protected from spambots. You need JavaScript enabled to view it.
b* Corresponding author: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Objective This study aims to design and optimize a multi-epitope vaccine against Dabie bandavirus (DBV) using bioinformatics approaches, and to systematically evaluate its structural stability, antigenicity, and immunogenicity, thereby providing a theoretical basis for novel vaccine development. Methods Helper T lymphocyte, cytotoxic T lymphocyte, and B-cell epitopes were identified and filtered according to their antigenicity, allergenicity and toxicity. The selected epitopes were then assembled with appropriate linkers and fused with the adjuvant β-defensin II to generate a vaccine candidate. Its physicochemical properties and structural characteristics were examined through secondary and tertiary structure prediction and subsequent refinement. To evaluate how the vaccine associates with immune receptors, molecular docking experiments were conducted. HLA-A*02:01, HLA-DRB1*01:01, TLR2, and TLR4 was docked to the vaccine, then we use molecular dynamics simulations to assess the stability of the protein complex. Population coverage and immune response profiles were further analyzed using in silico methods. Results The putative epitopes all exhibited strong antigenicity and posed no potential harm to humans. All selected epitopes and the adjuvant were constructed into the final vaccine, and further evaluation was conducted by calculating its physicochemical properties. Taken together, these findings indicate that the multi-epitope vaccine was structurally stable. Overall,given its design, this vaccine emerges as a highly promising candidate for subsequent experimental development.
© The Authors, published by EDP Sciences, 2026
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.

